Multiple Myeloma

Dr Fonseca
Videos
Dr Fonseca Highlights Phase 2 GRIFFIN Study Results for Newly Diagnosed MM
12/13/2021
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic,...
12/13/2021
Oncology
pgr
Conference Coverage
Safety and Tolerability Analysis of Melflufen plus Dexamethasone in Patients with Relapsed/Refractory MM
12/01/2021
Melfulen plus dexamethasone shows consistent safety and tolerability when compared to pomalidomide and dexamethasone.
Melfulen plus dexamethasone shows consistent safety and tolerability when compared to pomalidomide and dexamethasone.
Melfulen plus dexamethasone...
12/01/2021
Oncology
Conference Insider
Combination Daratumumab and Dexamethasone Shows Promising Efficacy in Patients with RRMM and Severe Renal Impairment
12/01/2021
Daratumumab, in combination with dexamethasone, demonstrated promising efficacy with manageable safety in patients with RRMM and severe renal impairment or on dialysis.
Daratumumab, in combination with dexamethasone, demonstrated promising efficacy with manageable safety in patients with RRMM and severe renal impairment or on dialysis.
Daratumumab, in combination with...
12/01/2021
Oncology
mm
Conference Coverage
Ixazomib and Daratumumab Demonstrate Tolerable Safety for Elderly Patients with Relapsed/Refractory MM
12/01/2021
When given to elderly and frail patients with relapsed/refractory MM, combination ixazomib and daratumumab, without dexamethasone, showed favorable safety.
When given to elderly and frail patients with relapsed/refractory MM, combination ixazomib and daratumumab, without dexamethasone, showed favorable safety.
When given to elderly and frail...
12/01/2021
Oncology
mm
Conference Coverage
Ruxolitinib with Steroids Shows Promise in Patients with Relapsed/Refractory MM
11/30/2021
Ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with relapsed/refractory MM.
Ruxolitinib in combination with steroids is a promising treatment option for heavily pretreated patients with relapsed/refractory MM.
Ruxolitinib in combination with...
11/30/2021
Oncology
Videos
Surbhi Sidana, MD, Discusses MGTA-145 Plus Plerixafor for Same-Day HSC Mobilization in MM
07/09/2021
Surbhi Sidana, MD, discusses a phase 2 study of MGTA-145 plus plerixafor for same-day HSC mobilization for autologous transplant in patients with MM. These data were presented at the 2021 ASCO Annual Meeting.
Surbhi Sidana, MD, discusses a phase 2 study of MGTA-145 plus plerixafor for same-day HSC mobilization for autologous transplant in patients with MM. These data were presented at the 2021 ASCO Annual Meeting.
Surbhi Sidana, MD, discusses a...
07/09/2021
Oncology
Videos
Amrita Krishnan, MD, FACP, Talks Teclistamab for Patients With MM
06/09/2021
Dr Krishnan shares findings from a phase 3 trial of teclistamab therapy for relapsed/refractory MM. These data were presented at the 2021 ASCO Annual Meeting.
Dr Krishnan shares findings from a phase 3 trial of teclistamab therapy for relapsed/refractory MM. These data were presented at the 2021 ASCO Annual Meeting.
Dr Krishnan shares findings from...
06/09/2021
Oncology
Dr Usmani
Videos
BCMA-Directed CAR-T Therapy Yields Durable Responses in Heavily Pretreated R/R MM
06/08/2021
Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.
Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.
Saad Usmani, MD, shares findings...
06/08/2021
Oncology
Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM
Videos
Ajai Chari, MD, Talks Talquetamab for Relapsed/Refractory MM
12/05/2020
In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.
In this video, Dr Chari discusses the findings of a phase 1 trial examining the use of talquetamab in heavily pretreated patients with relapsed/refractory MM.
In this video, Dr Chari...
12/05/2020
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use